Saturday 17 October 2026 Export CLGN’s income statement to Excel — free account

CollPlant Biotechnologies Ltd. Sponsored ADR

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.60 0.08 −2.17%

Follow CLGN

Alert me

Market cap: $7.0M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 4/9
Altman Z: −16.87
Beneish M: −3.20
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 6.96

Revenue 0.32

Net Income (12.51)

Free Cash Flow (11.20)

Net Debt (2.95)

Current Ratio 1.57

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.71)

P/S ratio 16.34

P/B ratio 1.76

Past 5Y EPS Growth —

This Y EPS Growth 35.10%

Next Y EPS Growth 69.24%

Next Y revenue growth 157.57%

Next 5Y EPS Growth 43.71%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.98%

10-year low 10-year high

P/B against its own 10 years 9.88%

10-year low 10-year high

EV/Sales against its own 10 years 60.59%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	27	12	6	3
Receivables	0	1	0	0
Inventory	1	0	1	1
Other	—	—	—	—
	28	13	7	4

	2023	2024	2025	Q'26
Payables	1	1	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	3	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(17.32%)	99.41%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	6.32%	(42.68%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	2	0	0	0	2
’24	0	0	0	0	1
’23	0	10	0	0	11
’22	0	0	0	0	0
’21	15	1	0	0	16
’20	1	1	4	1	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(1)	(2)	(3)	(3)	(9)
’24	(3)	(4)	(3)	(3)	(14)
’23	(3)	(4)	7	(2)	(3)
’22	(3)	(4)	(3)	(3)	(14)
’21	11	(3)	(3)	(2)	3
’20	(3)	(2)	1	(2)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(1)	(2)	(3)	(3)	(9)
’24	(3)	(4)	(4)	(4)	(15)
’23	(4)	(4)	7	(3)	(4)
’22	(4)	(4)	(4)	(4)	(15)
’21	11	(4)	(3)	(3)	1
’20	(3)	(2)	1	(2)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.30)	(1.89)	—	—	—
’25	(1.30)	(2.80)	(2.70)	(2.58)	(9.40)
’24	(3.70)	(3.70)	(3.80)	(3.40)	(14.50)
’23	(3.30)	4.90	(3.80)	(4.20)	(6.20)
’22	(3.60)	(3.90)	(4.00)	(3.90)	(15.30)
’21	8.80	(3.00)	(2.90)	(3.00)	0.20
’20	(2.40)	(2.80)	0.70	(4.20)	(8.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	31.30	33.50	56.24	102.50	42.70	47.00	32.40	13.00	Analyst estimates 2026–2028 Powerpack
	High	—	—	89.90	61.30	145.50	242.60	168.20	139.70	67.50	49.80
People
People	Employees	27	29	40	46	52	66	73	75	57	39
	Revenue/emp, $m	0.00	0.02	0.13	0.05	0.12	0.24	0.00	0.15	0.01	0.06
Income, $m
Income, $m	Revenue	0	0	5	2	6	16	0	11	1	2
	Gross margin, %	100.00	96.88	66.91	18.94	51.08	87.18	(33.78)	81.83	(215.53)	64.78
	EBT	(8)	(6)	(6)	(11)	(6)	0	(17)	(7)	(17)	(11)
	EBT margin, %	(9,522.89)	(1,251.98)	(124.63)	(481.62)	(94.09)	1.52	(5,660.54)	(64.05)	(3,225.05)	(484.56)
	Net income	(8)	(6)	(6)	(11)	(6)	0	(17)	(7)	(17)	(11)
	Depreciation	0	0	0	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.41	1.81	11.43	4.65	8.91	15.69	0.27	9.62	0.45	1.94
	Earnings	(39.27)	(22.60)	(14.25)	(22.40)	(8.40)	0.20	(15.30)	(6.20)	(14.50)	(9.40)
	Cash flow	(27.26)	(19.36)	(2.78)	(11.44)	(6.46)	2.51	(12.42)	(2.43)	(12.30)	(7.72)
	Capex	(0.69)	(0.48)	(1.90)	(2.93)	(0.75)	(1.56)	(1.19)	(0.78)	(0.42)	(0.02)
	Free cash flow	(27.95)	(19.85)	(4.67)	(14.37)	(7.22)	0.95	(13.61)	(3.20)	(12.72)	(7.74)
	Book value	7.26	9.84	12.36	8.20	6.50	45.26	29.26	24.88	11.76	4.98
	Shares, m	0	0	0	0	1	1	1	1	1	1
Valuation, ×
Valuation, ×	P/E	8.86	8.86	0.00	0.00	0.00	74.36	0.00	0.00	0.00	0.00
	P/S	54.76	54.76	3.67	12.26	12.09	10.43	317.34	6.29	80.07	7.21
	P/B	9.90	9.90	3.40	6.95	16.57	3.61	2.94	2.43	3.06	2.81
	EV/Sales	51.64	51.64	2.58	12.98	12.43	8.01	236.33	4.33	67.05	7.00
	EV/FCF	0.00	0.00	(6.32)	(4.20)	(15.61)	132.52	(4.71)	(12.85)	(2.36)	(1.75)
Cash, $m
Cash, $m	Operating cash flow	(5)	(5)	(1)	(6)	(4)	3	(14)	(3)	(14)	(9)
	Capex	0	0	(1)	(1)	(1)	(2)	(1)	(1)	0	0
	Free cash flow	(6)	(5)	(2)	(7)	(5)	1	(15)	(4)	(15)	(9)
Balance, $m
Balance, $m	Working capital	0	5	5	2	2	42	29	25	10	4
	Total debt	0	4	0	0	3	4	3	—	—	—
	Net debt	(1)	(1)	(5)	(4)	(3)	(43)	(30)	(27)	(12)	(6)
	Shareholders’ equity	1	3	5	4	4	45	32	28	13	6
Returns, %
Returns, %	ROA	(129.91)	(98.89)	(74.21)	(114.48)	(53.48)	0.76	(38.04)	(19.53)	(62.87)	(77.90)
	ROIC	(1,044.57)	(326.75)	0.00	(1,543.49)	(309.13)	2.25	(410.20)	(329.47)	(824.30)	(5,478.53)
	ROE	(387.61)	(294.98)	(155.43)	(234.83)	(134.83)	0.96	(43.73)	(23.16)	(79.46)	(117.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 6 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CALC CalciMedica Inc.	$7.4M	— (loss-making)	—	—	n/m	+31.42% (above 0%: growing)	0.00%	0.00%	Compare
XCUR Exicure, Inc.	$7.3M	— (loss-making)	— (loss-making)	−80.51% (below 0%: shrinking)	n/m	+65.38% (above 0%: growing)	100.00%	0.00%	Compare
SKYE Skye Bioscience, Inc.	$7.0M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
BCLI Brainstorm Cell Therapeutics Inc.	$7.0M	— (loss-making)	—	—	n/m	+74.44% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.0M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)
NIKI Niki BioSolutions, Inc.	$6.9M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
AIM AIM ImmunoTech Inc.	$6.8M	— (loss-making)	— (loss-making)	+4.00% (above 0%: growing)	n/m	−167.46% (below 0%: shrinking)	80.77%	(13,511.54%)	Compare
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
Median of peers	$7.0M	—	—	−34.71%	—	+33.13%	72.71%	0.00%

All 614 Biotechnology stocks →

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) key facts

Strength: CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024.
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, CLGN traded at $3.60, a market capitalization of $7.0 million.
Return on equity was −117.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −16.87 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 6, 2026.